{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T01:28:12Z","timestamp":1791163692213,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.leukres.2011.09.011","type":"journal-article","created":{"date-parts":[[2011,10,10]],"date-time":"2011-10-10T13:05:44Z","timestamp":1318251944000},"page":"212-218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"title":["Bortezomib resistance in a myeloma cell line is associated to PSM\u03b25 overexpression and polyploidy"],"prefix":"10.1016","volume":"36","author":[{"given":"Patricia","family":"Balsas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Gal\u00e1n-Malo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Marzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Naval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2011.09.011_bib0005","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2141.2007.06585.x","article-title":"Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma","volume":"137","author":"Richardson","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2011.09.011_bib0010","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10238-007-0134-y","article-title":"New therapies in multiple myeloma","volume":"7","author":"Merchionne","year":"2007","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.leukres.2011.09.011_bib0015","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2011.09.011_bib0020","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1182\/blood-2008-07-167767","article-title":"Many facets of bortezomib resistance\/susceptibility","volume":"112","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.09.011_bib0025","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","article-title":"Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSM\u03b25) gene mutation and overexpression of PSM\u03b25 protein","volume":"112","author":"Oerlemans","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.09.011_bib0030","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1038\/leu.2009.8","article-title":"Characterization of the ubiquitin\u2013proteasome system in bortezomib-adapted cells","volume":"23","author":"Ruckrich","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2011.09.011_bib0035","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/leu.2010.137","article-title":"Bortezomib-resistant myeloma cell lines: a role for mutated PSM\u03b25 in preventing the accumulation of unfolded proteins and fatal ER stress","volume":"24","author":"Ri","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2011.09.011_bib0040","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.bcp.2008.11.024","article-title":"Cooperation between Apo2L\/TRAIL and bortezomib in multiple myeloma apoptosis","volume":"77","author":"Balsas","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.leukres.2011.09.011_bib0045","first-page":"589","article-title":"Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay","volume":"48","author":"Alley","year":"1988","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2011.09.011_bib0050","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/bjc.1988.63","article-title":"Activation of murine \u2018T\u2019 lymphomas in the presence of a human myeloma cell line, RPMI-8226, in vivo","volume":"57","author":"Millar","year":"1988","journal-title":"Br J Cancer"},{"key":"10.1016\/j.leukres.2011.09.011_bib0055","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/46.5.673","article-title":"Proteasome inhibition measurements: clinical application","volume":"46","author":"Lightcap","year":"2000","journal-title":"Clin Chem"},{"key":"10.1016\/j.leukres.2011.09.011_bib0060","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0962-8924(98)01346-4","article-title":"Proteasome inhibitors: valuable new tools for cell biologists","volume":"8","author":"Lee","year":"1998","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.leukres.2011.09.011_bib0065","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1182\/blood-2008-08-174797","article-title":"Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells","volume":"113","author":"Miller","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.09.011_bib0070","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1182\/blood-2007-12-130823","article-title":"Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA","volume":"112","author":"Nawrocki","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.09.011_bib0075","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.canlet.2009.03.013","article-title":"Histone deacetylase inhibitors as anti-neoplastic agents","volume":"280","author":"Batty","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1016\/j.leukres.2011.09.011_bib0080","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.bbamcr.2007.05.007","article-title":"Adaptive modification and flexibility of the proteasome system in response to proteasome inhibition","volume":"1773","author":"Naujokat","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.leukres.2011.09.011_bib0085","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1124\/jpet.108.138131","article-title":"Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma\/leukemia line","volume":"326","author":"Lu","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.leukres.2011.09.011_bib0090","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.leukres.2005.06.014","article-title":"No evidence of mutations of the PSM\u03b25 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib","volume":"30","author":"Politou","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2011.09.011_bib0095","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.leukres.2010.01.013","article-title":"Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient","volume":"34","author":"Yuan","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2011.09.011_bib0100","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrm2163","article-title":"The spindle-assembly checkpoint in space and time","volume":"8","author":"Musacchio","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.leukres.2011.09.011_bib0105","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin\u2013proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.09.011_bib0110","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.drudis.2010.01.008","article-title":"Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy","volume":"15","author":"Dick","year":"2010","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.leukres.2011.09.011_bib0115","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/10428190701817258","article-title":"Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma","volume":"49","author":"Richardson","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2011.09.011_bib0120","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/leu.2009.41","article-title":"The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia\/lymphoma cells apoptosis","volume":"23","author":"Zhang","year":"2009","journal-title":"Leukemia"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212611004346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212611004346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T16:43:21Z","timestamp":1777999401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212611004346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0145212611004346"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2011.09.011","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bortezomib resistance in a myeloma cell line is associated to PSM\u03b25 overexpression and polyploidy","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2011.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}